Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,069 across all filing types
Latest filing 2019-09-04 Board/Management Inform…
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Oasmia completes its management team
Board/Management Information Classification · 100% confidence The document announces the recruitment of new General Managers and provides an updated list of the company's management team. While it mentions an attachment, the core content is a press release regarding changes in senior management. According to the filing definitions, announcements of changes in the board or senior management fall under the 'MANG' category.
2019-09-04 English
Oasmia completes its management team
Board/Management Information Classification · 98% confidence The document explicitly announces the recruitment of new General Managers and other key employees, detailing their extensive experience and the structure of the newly completed management team. This content directly aligns with the definition of 'Board/Management Information'. The presence of an attachment link and the short length suggest it might also be an announcement, but the core subject matter is management changes, making MANG the most specific fit over RPA or RNS.
2019-09-04 English
Notice of Annual General Meeting in Oasmia Pharmaceutical AB
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal 'Notice of Annual General Meeting' for Oasmia Pharmaceutical AB. It outlines the agenda, proposals for shareholder voting (such as board elections, remuneration, and share capital amendments), and instructions for attendance. While it mentions that the Annual Report will be available, the document itself is the invitation/proxy solicitation material for the meeting. According to the provided definitions, materials sent to shareholders to provide information and request votes for meetings are classified as Proxy Solicitation & Information Statement (PSI).
2019-08-28 English
Kallelse till årsstämma i Oasmia Pharmaceutical AB
AGM Information Classification · 99% confidence The document is a formal notice of an Annual General Meeting (AGM) for Oasmia Pharmaceutical AB. It contains the agenda, proposals for board decisions, and instructions for shareholders to attend. While it mentions that the annual report will be available, the document itself is the invitation/proxy solicitation material for the meeting, which falls under the category of Proxy Solicitation & Information Statement (PSI).
2019-08-28 Swedish
Notice of Annual General Meeting in Oasmia Pharmaceutical AB
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal 'Notice of Annual General Meeting' for Oasmia Pharmaceutical AB. It outlines the agenda, proposals for shareholder voting (such as board elections, remuneration, and share capital amendments), and instructions for attendance. While it mentions that the Annual Report will be available, the document itself is the invitation/proxy solicitation material for the meeting. According to the provided definitions, materials sent to shareholders to provide information and request votes for meetings are classified as Proxy Solicitation & Information Statement (PSI).
2019-08-28 English
Kallelse till årsstämma i Oasmia Pharmaceutical AB
AGM Information Classification · 99% confidence The document is a formal notice of an Annual General Meeting (AGM) for Oasmia Pharmaceutical AB. It contains the agenda, proposals for board decisions, and instructions for shareholders to attend. While it mentions that the annual report will be available, the document itself is the invitation/proxy solicitation material for the meeting, which falls under the category of Proxy Solicitation & Information Statement (PSI).
2019-08-28 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.